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Summary.-Xenografts of 3 human malignant cell lines in congenitally athymic
nude mice have been examined for susceptibility to BCG. Growth of all 3 tumours,
a bladder carcinoma, a melanoma and a colon carcinoma, was suppressed when
cells were injected in admixture with BCG. Distant injection of BCG was ineffective.
Mice with progressive growths had no detectable anti-human antibody, and rejec-
tion of cells and BCG failed to confer protection against subsequent tumour challenge.
These studies indicate that human malignant cells are susceptible to local BCG-
activated host responses, and that athymic mouse xenografts may be a useful model
for assessing the response of human tumours to such agents.
FOLLOWING THE WORK of Morton et al.
(1970), it is well established that intra-
lesional injection of Bacillus Calmette-
Gue'rin (BCG) into cutaneous melanoma
lesions in man may cause their regression
(Goodnight & Morton, 1978). Other tum-
ours, including those of breast (Smith et
al., 1973), bladder (Morales et al., 1978) and
prostate (Merrin et al., 1975) have been
shown to regress after local infiltration
with BCG, and recently intrapleural BCCQ
has been reported to prolong post-
operative survival of Stage I lung cancer
patients (McKneally et al., 1976, 1978).
While comparable studies with a wide
range of experimental animal tumours
have also shown their susceptibility to
locally applied bacterial adjuvants, princi-
pally BCG and C. parvum (reviewed by
Milas & Scott, 1978; Baldwin & Pimm,
1978), experimental techniques for study-
ing the susceptibility of human tumours
to this form of adjuvant contact suppres-
sion are clearly limited. However, in
view of the current use of human tumour
xenografts in mice for assessing their
response to chemotherapeutic agents
(Sonis et al., 1977; UICC Technical
Report, 1974; Povlsen & Jacobsen 1975;
Houghton & Houghton, 1978), the present
tests were carried out to examine their
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susceptibility to BCG. These studies were
modelled on those previously carried out
with rat tumour xenografts in congenitally
athymic nude mice (Pimm & Baldwin,
1975, 1976).
MATERIALS AND METHODS
Tumour lines.-Bladder carcinoma, Line
T24, was obtained from Dr Michael Moore,
Patersoin Laboratories, Christie Hospital and
Holt Radium Institute, Manchester.
Colon carcinoma, Line HT-29 was obtained
from Dr L. M. Franks, Imperial Cancer
Research Fund Laboratories, London.
Melanoma, Line Mel-S, was obtained from
Dr C. Sorg, Universitiits-Hautklinik,
Mtinster.
Lines were maintained by in vitro passage
in Eagle's medium supplemented with 20%
foetal calf serum.
Bacillus Calmette-Guerin.-Freeze-dried
BCG vaccine (percutaneous) was supplied by
Glaxo Laboratories, Greenford, Middlesex.
On reconstitution this vaccine contains
50-250 x 106 viable units in 3 mg moist wt/
ampoule.
Athymic mice.-Athymic (CBA nu/nu or
ONU nu/nu) mice and heterozygous mice
(CBA nu/ +) were purchased from MRC
Laboratory Animal Centre, Carshalton, Sur-
rey. They were fed standard laboratory diet
(Oxoid) and tapwater ad libitum, whileM. V. PIMM AND R. W. BALDWIN
housed in all-plastic cages with sawdust
bedding in a Filter Rack Ventilation Cabinet
(Anglia Laboratory Animals, Alconbury,
Huntingdon, Cambridge).
Antihuman serum.-Heterozygous (nu/+)
CBA mnice received 2 i.p. injections at 14-
day intervals of 106 normal human lympho-
cytes or culture-derived T24 bladder carcin-
oma cells. They were bled from the heart 10
days after the second injection and sera
stored at -20°C.
Indirect membrane-immunofluorescence tests.
-Mouse sera were tested for antibody
against tumour cells by an indirect
membrane-immunofluorescence test against
viable cells in suspension, harvested from
tissue culture or prepared by trypsin diges-
tion of minced tissue taken froin xenograft
growths in athymic mice. 2-5 x 106 cells
were incubated for 20 min at room tempera-
ture with 041 ml serum, washed x4 in
Medium 199, resuspended in 01 ml fluores-
cein-labelled goat anti-mouse globulin (Nor-
dic Diagnostics, Londoin, diluted 1/30) for 20
min, and finally washed x4 and suspended
in 1: 1 (v/v) glycerol: phosphate-buffered
saline (pH 7.2). Cells were examined with a
Reichert fluorescence microscope and cells
showing complete or partial membrane
fluoreseence scored as positively stained.
Normal mouse serum (nu/nu or nu/+) was
used as negative control and a fluorescence
index (FI) calculated for each test serum
as:
FL
00 cells unstained 0O cells unstained
by normal serum by test serum
/O cells unstained by normal serum
Experimental protocol.-Cells were harves-
ted from in vitro culture, washed and re-
suspended in Medium 199 or prepared from
solid growths in athymic mice by digestion of
minced tissue in 0.25% trypsin. Defined cell
numbers were injected s.c. into groups of
athymic mice alone or in admixture with
BCG organisms. In one test, BCG was injected
separately, by the i.p. route. Mice rejecting
mixed inocula of tumour cells and BCG were
in some cases challenged at a contralateral
s.c. site with tumour cells alone.
RESULTS
Growth and BCG suppression of tumours
Groups of mice were injected s.c. with
1-2 x 106 human tumour cells, harvested
from tissue culture or prepared by trypsin
digestion of xenograft growths, alone or
in admixture with BCG (Table I).
With all 3 tumours progressive growth
occurred in the majority of mice receiving
tumour cells alone. In contrast, admixture
with BCG (0 5 mg moist wt) prevented
tumour development in all animals (Table
I). BCCG injected at a distant, i.p. site
failed to control growth of an s.c. chal-
TABLE I.-BCG suppression of humian tumour xenografts in athymic nude mice
Mixe(d s.c. inocultum Challenge inoculum
Tumour takes Ttumour takes
No. cells BCG No. cells
Tumour ( x 106) (mg) Test Control ( x 10(;) Test Cointrol
Melanoma
Mel-S/TC*
Colon carcinoma
HT-29/TC/AMt
Bladder carcinoma
T24/TC
I (0 -05 0/2 5/6
1 0 . 5 0/2 2/2
1 0 ,5 0/3 2/2
2
1
2
I
(05 0/2
05 0/5
0 5 0/2
0 , 51 3/3
2/2
3/5
2/2
3/3
* TC cells harveste(d fiom tissue cutltuire.
t AM cells prepared fiom xenograft growths in athymic mice.
I BCG injecte(d i.p.
3/3 3/3
2/2 3/3
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lenge. Groups of mice rejecting tumour
cells and BCG were subsequently chal-
lenged s.c. in the opposite flank with cells
alone of the same tumour (Table I). There
was no resistance to this second challenge,
tumour growing out in all mice, and in
new control animals.
Characteristics of xenograft growths
Tumours developed as discrete en-
capsulated growths, with no macro-
scopically visible metastases. The mela-
noma Mel-S showed macroscopically vis-
ible pigmentation. To confirm that
growths initiated in the mice from culture-
derived tumour lines were indeed human,
indirect membrane-immunofluorescence
tests were carried out with mouse anti-
human serum on viable cells brought into
suspension (Table II). Cells from growths
TABLE II. Immunofuorescence reactions
(FI) of anti-human sera* against cells
from athymic mouse xenografts
Ft against tar-get
cells dlerivecd from
Tissue Athymic
Turnouti cullttIre moluse
Melanoma-Mel-S 0* 95
Coloni carcinoma-HT29 1 00
Bladder carcinoma-T24 1 0( 1 00
* Raise(d in heterozygouis 00/- mice against
human lymphocytes.
of all 3 tumour types reacted strongly
with serum raised in heterozygous (nu/ +-)
mice against human peripheral lympho-
cytes. The lack of complete reactivity of
serum against cells from digests of Mel-S
growths (Fl 0-95) could be a reflection of
the presence of host (mouse) cells in the
preparation, but the complete reactivity
against HT29 and T24 does not imply
that mouse stroma and blood vessels are
not an integral part of these growths,
rather that the technique of tumour
digestion and cell handling may not be
suitable for the recovery of such cells.
Immunofuorescence tests with xenograft-
bearing mouse sera
Sera collected from 3 athymic mice
bearing xenografts of the bladder car-
cinoma T24 were tested for anti-human
antibody by the indirect membrane-
immunofluorescence test against T24 cells
prepared from growths in athymic mice or
harvested from in vitro culture (Table
III). None of the sera reacted against
T24 cells (Fl 0-00-001), although serum
from heterozygous (nu/+) mice rejecting
T24 cells reacted strongly (FT 0 79-1.00).
DISCUSSION
These studies demonstrate that cells
of human tumours will produce progres-
sive growth in congenitally athymic mice,
and that this growth is prevented by BCG
incorporated into the inoculum, not in-
jected separately. Sere raised in hetero-
zygous mice against normal human cells
reacted with cells from xenografts, con-
firming the human characteristic of the
cells.
In previous work, growth of rat tumour
xenografts was similarly controlled by
admixture with BCG or C. parvum
(Pimm & Baldwin, 1975, 1976), although
the suippression in athymic mice was in
accordance with that seen in syngeneic
recipients, so that carcinogen-induced
sarcomas and hepatomas were readily
controlled, while only slight suppression
TABLE III.-Imnmunofluorescence reactions of serafrom athymic mice
bearing xenografts of human bladder carcinoma T24
Serum (lonor tumourl
Age AMean cliam.
(days) (cm)
81 1-4
81 1 4
74 1 7
(ulo+I) anti-T24 seiulrn
Immunofluorescence ieactioni
Target cells Fl
T24-tissue cultuire 0 .00
T24-athymic mouse 0*00
T24-athymic mouse 0 01
T24-tissue culture 0 * 79-1 * 00
Cells injecte(l
i0 vitro
passage
T24/8
T24/8
T24/8
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of a carcinogen-induced mammary carci-
noma was achieved in either syngeneic
rats or athymic mice.
There is considerable evidence, from
workwith syngeneicallytransplanted tum-
ours and with athymic mouse xeno-
grafts, that tumour suppression by locally
applied BCG is dependent upon local
activation of host macrophages. Thus the
response against rat tumours, both in
syngeneic animals and athymic mice, is
abrogated by depletion of host phago-
cytic cells with silica or carrageenan
(Chassoux & Salomon, 1975; Hopper
et al., 1976; Moore & Nisbet, 1978;
Keller, 1977). The indication from the
present work is that locally activated
host responses can similarly control
growth of human malignant cells in an
in vivo environment. This too is unlikely
to involve systemic immunological respon-
ses, since distantly injected BCG was
ineffective, and mice rejecting human
malignant cells and BCG were not im-
mune to a challenge with cells alone.
Also immunofluorescence tests with sera
from mice bearing xenografts failed to
detect anti-human antibody. These obser-
vations parallel previous studies with
rat tumour xenografts, where athymic
mice rejecting cells and BCG were not
immune to further challenge, and had no
detectable anti-rat antibody (Pimm &
Baldwin, 1975, 1976; Pimm, 1977).
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